]>
IRCT20170224032753N2 IRCT 2020-03-22 Bandare-abbas University of Medical Sciences "Comparison the Effect of Intravenous Ketamine with Standard Treatment in Migraine Patients" Comparison the Effect of Intravenous Ketamine with Standard Treatment in Migraine Patients Admitted to Emergency Department 2019-10-21 anticipated 46 Complete https://irct.ir/trial/42709 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 3 Migraine headache. Intervention 1: Intervention group: will receive IV ketamine 1mg/kg in addition to standard treatment including 30mg IV Ketorolac and 10mg IV metoclopramide, The designated drug was diluted with 10 ml distilled water for 3 to 5 minutes. Intervention 2: Control group: received first-line standard treatment including 30mg IV Ketolol and 10mg IV metoclopramide. No - There is not a plan to make this available Justification or reason for not sharing IPD is To protect the secrets of patients participating in the project
public Mohammad Javad Khorasani
Shahid Mohammadi Hospital, Jomhoorieslami Blvd.
Bandarabbas Iran (Islamic Republic of) 7919915519 +98 76 3334 7000 khorasani@hums.ac.ir Bandare-abbas University of Medical Sciences scientific Mohammad Javad Khorasani
Shahid Mohammadi Hospital, Jomhoorieslami Blvd.
Bandarabbas Iran (Islamic Republic of) 7919915519 +98 76 3334 7000 khorasani@hums.ac.ir Bandare-abbas University of Medical Sciences Iran (Islamic Republic of) Known migraine patients ,referring to emergency department of Shahid Mohammadi hospital in Bandarabbas Age between 18 _ 70 years 18 years 70 years Both history of cardiac disease not complete the written consent oxygen saturation level below 92 percent systolic blood pressure below 90 or over 180 mmHg heart rate below 50 or higher than 120 beat per minute respiratory rate below 10 or higher than 30 per minute consuming any analgesic 4 hour prior to study pregnancy or lactation liver cirrhosis history of drug reaction with morphine or ketamine or other drugs used in the study patients who are on dialysis weight under 45 or more than 115 kg presence of brain mass, chronic pulmonary disease , history of psychosis , or brain damage G43 Migraine Treatment - Drugs Treatment - Drugs Intervention group: will receive IV ketamine 1mg/kg in addition to standard treatment including 30mg IV Ketorolac and 10mg IV metoclopramide, The designated drug was diluted with 10 ml distilled water for 3 to 5 minutes. Control group: received first-line standard treatment including 30mg IV Ketolol and 10mg IV metoclopramide. Headache intensity. Timepoint: Before treatment, 30 , 60 and 90 minutes after treatment. Method of measurement: Visual Analogue Scale. Bandarabbas University of Medical Sciences Approved 2019-05-19 Iran National Comittee for Ethics in Biomedical Research International Affairs and Scientific Collaborations, Vice-Chancellery for Education of Hormozgan University of Medical Sciences (HUMS),Jomhuri Eslami Blvd, Bandar Abbas, Iran Bandarabbas Hormozgan Iran (Islamic Republic of)